Identifying and managing factors that interfere with or worsen blood pressure control

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 35-48

  Basile, Jan N ^a   Bloch, Michael J ^b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Hypertension

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ANTIHYPERTENSIVE AGENT; COCAINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DECONGESTIVE AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; EPHEDRA SINICA EXTRACT; ERYTHROPOIETIN; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUCOCORTICOID; HYPERICUM PERFORATUM EXTRACT; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PSEUDOEPHEDRINE; SIBUTRAMINE; SOUR ORANGE EXTRACT; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE;

ALCOHOL WITHDRAWAL; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIGESTIVE SYSTEM ULCER; HEART FAILURE; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MEASUREMENT ERROR; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PHYSICIAN ATTITUDE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; RENOVASCULAR HYPERTENSION; RISK FACTOR; SLEEP APNEA SYNDROME; SMOKING CESSATION; STROKE; SYSTOLIC BLOOD PRESSURE; THYROID DISEASE; TREATMENT PLANNING; WHITE COAT HYPERTENSION; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CASE REPORT; DIET; DRUG INTERACTION; DRUG RESISTANCE; FEMALE; LIFESTYLE; PAIN; REVIEW; TREATMENT FAILURE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIET; DRUG INTERACTIONS; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; LIFE STYLE; PAIN; PATIENT COMPLIANCE; RISK FACTORS; TREATMENT FAILURE;

EID: 77950362361     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2120     Document Type: Article

References (78)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21-e181.
2. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control-continued disparities in adults: United States,2005-2006. Hyattsville, MD: National Center for Health Statistics; 2008.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
4. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of bloodpressure-related disease, 2001. Lancet. 2008;371(9623):1513-1518.
5. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6(4):e1000058.
6. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155(7):701-709.
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
8. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761-2788.
9. Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens. 2004;22(9):1707-1716.
10. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299-305.
11. Ostchega Y, Hughes JP, Wright JD, McDowell MA, Louis T. Are demographic characteristics, health care access and utilization, and comorbid conditions associated with hypertension among US adults? Am J Hypertens. 2008;21(2):159-165.
12. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults1999-2004. Hypertension. 2007;49(1):69-75.
13. Howard DL, Carson AP, Holmes DN, Kaufman JS. Consistency of care and blood pressure control among elderly African Americans and whites with hypertension. J Am Board Fam Med. 2009;22(3):307-315.
14. Plantinga LC, Miller ER 3rd, Stevens LA, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009;54(1):47-56.
15. McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med. 2009;150(8):505-515.
16. Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich). 2007;9(1 suppl 1):7-12.
17. Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med. 2004;15(6):348-357.
18. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;10(7 pt 2):481-486.
19. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351.
20. Heisler M, Hogan MM, Hofer TP, Schmittdiel JA, Pladevall M, Kerr EA. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008;117(22):2884-2892.
21. Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating "clinical inertia" from appropriate care. J Gen Intern Med. 2007;22(12):1648-1655.
22. Rose AJ, Shimada SL, Rothendler JA, et al. The accuracy of clinician perceptions of "usual" blood pressure control. J Gen Intern Med. 2008;23(2):180-183.
23. Basile JN. Clinical inertia and blood pressure goal attainment. J Clin Hypertens. 2009;11(suppl):S5-S12.
24. Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens. 2008;21(2):183-188.
25. Lagu T, Weiner MG, Eachus S, Tang SS, Schwartz JS, Turner BJ. Effect of patient comorbidities on filling of antihypertensive prescriptions. Am J Manag Care. 2009;15(1):24-30.
26. Shah NR, Hirsch AG, Zacker C, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392-396.
27. Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc. 2009;101(1):34-39.
28. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972-984.
29. Betancourt JR, Carrillo JE, Green AR. Hypertension in multicultural and minority populations: linking communication to compliance. Curr Hypertens Rep. 1999;1(6):482-488.
30. Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C. Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf. 2009;18(8):672-681.
31. Natarajan S, Santa Ana EJ, Liao Y, Lipsitz SR, McGee DL. Effect of treatment and adherence on ethnic differences in blood pressure control among adults with hypertension. Ann Epidemiol. 2009;19(3):172-179.
32. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117-1124.
33. Appel LJ, Champagne CM, Harsha DW, et al; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289(16):2083-2093.
34. Calhoun DA, Jones D, Textor S, et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-e526.
35. Sloand JA, Balakrishnan SL, Fong MW, Bisognano JD. Evaluation and treatment of resistant hypertension. Cardiol J. 2007;14(4):329-330.
36. Viera AJ, Hinderliter AL. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician. 2009;79(10):863-869.
37. de Leeuw PW. Drug-induced hypertension. Recognition and management in older patients. Drugs Aging. 1997;11(3):178-185.
38. Murphy CA, Dargie HJ. Drug-induced cardiovascular disorders. Drug Saf. 2007;30(9):783-804.
39. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749-1757.
40. McFadden CB, Brensinger CM, Berlin JA, Townsend RR. Systematic review of the effect of daily alcohol intake on blood pressure. Am J Hypertens. 2005;18(2 pt 1):276-286.
41. Chen L, Davey Smith G, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008;5(3):e52.
42. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004;38(5):613-619.
43. Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and coronary heart disease: a meta-analysis. Addiction. 2000;95(10):1505-1523.
44. Bagnardi V, Zatonski W, Scotti L, La Vecchia C, Corrao G. Does drinking pattern modify the effect of alcohol on the risk of coronary heart disease? Evidence from a meta-analysis. J Epidemiol Community Health. 2008;62(7):615-619.
45. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233.
46. Gyamlani G, Geraci SA. Secondary hypertension due to drugs and toxins. South Med J. 2007;100(7):692-699; quiz 700, 708.
47. Salerno SM, Jackson JL, Berbano EP. The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature. J Hum Hypertens. 2005;19(8):643-652.
48. Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med. 2005;165(15):1686-1694.
49. Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine: systematic review and metaanalysis. Ann Pharmacother. 2007;41(3):381-390.
50. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164(9):994-1003.
51. Coupland N, Wilson S, Nutt D. Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol. 1997;11(1):83-92.
52. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand. 2008;118(6):434-442.
53. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005;20(5):327-341.
54. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59(10):502-508.
55. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94(3):483-489.
56. Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception. 2004;69(2):89-97.
57. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8(15 suppl):S383-S391.
58. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905-1915.
59. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167(4):394-399.
60. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500-507.
61. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289-300.
62. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477-484.
63. Johnson AG. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging. 1998;12(1):17-27.
64. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-496.
65. Schwartz JI, Thach C, Lasseter KC, et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. J Clin Pharmacol. 2007;47(12):1521-1531.
66. Stricker K, Yu S, Krammer G. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. BMC Musculoskelet Disord. 2008;9:118.
67. Sowers JR, White WB, Pitt B, et al; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161-168.
68. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients _ or 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90(9):959-963.
69. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004;43(3):573-577.
70. Lohmander LS, McKeith D, Svensson O, et al; STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005;64(3):449-456.
71. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840-845.
72. Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol. 2009;36(6):1290-1297.
73. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
74. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.
75. Grover SA, Coupal L, Zowall H. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension. 2005;45(1):92-97.
76. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
77. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006(1):CD004257.
78. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy. 2007;27(9):1219-1230.